Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Published: 04-09-2020| Version 1 | DOI: 10.17632/j7mxzzbhc5.1
Contributor:
Lieneke Ariëns

Description

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Files